The authors suggest that besides correlated to poor survival, high B7-H3 expression may be correlated to refractoriness to anti-PD-1/programmed death-ligand 1 (PD-L1) immunotherapy by impairing CD8+ T-cell mediated tumor immunity. The gene discussed is CD8A; the disease is neoplasm.